CBD showed no clear advantage over placebo on primary behavior measures
Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial.
AI Summary
This randomized, double-blind, placebo-controlled crossover trial asked whether plant-derived CBD was safe and reduced severe problem behaviors in autistic boys aged 7–14. Participants received CBD for eight weeks and placebo for eight weeks, with a four-week washout between phases. The primary measures were the Repetitive Behavior Scale-Revised, Child Behavior Checklist, and Autism Diagnostic Observation Schedule-2.
On the primary behavior measures, both treatment phases showed improvement on two scales, but there was no significant difference between CBD and placebo. The ADOS-2 improved during the placebo phase only; that result was no longer evident after accounting for the children’s other medications. Blinded clinical impressions indicated behavioral improvement with CBD in almost two-thirds of participants, while one-third showed no change or improved on placebo. The abstract reports an acceptable safety profile and a strong placebo effect. Overall, the trial did not establish clear efficacy across the broad behaviors measured; this abstract-based summary cannot determine which children, if any, may benefit, and medication effects on CBD levels or outcomes may matter.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.